<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5617">
  <stage>Registered</stage>
  <submitdate>27/02/2012</submitdate>
  <approvaldate>27/02/2012</approvaldate>
  <nctid>NCT01588496</nctid>
  <trial_identification>
    <studytitle>Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities</studytitle>
    <scientifictitle>2-part, Phase 2/3 Study to Assess the Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia. Part A - Open-label, Single-arm, Multicenter Pilot Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia. Part B - Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia</scientifictitle>
    <utrn />
    <trialacronym>TESLA</trialacronym>
    <secondaryid>2011-005399-40</secondaryid>
    <secondaryid>20110233</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Homozygous Familial Hypercholesterolemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Evolocumab
Treatment: drugs - Placebo

Experimental: Part A: Evolocumab - Participants received open-label evolocumab 420 mg subcutaneously once a month for 12 weeks.

Experimental: Part B: Evolocumab - Participants received double-blind evolocumab 420 mg subcutaneously once a month for 12 weeks.

Placebo Comparator: Part B: Placebo - Participants received double-blind placebo subcutaneously once a month for 12 weeks.


Other interventions: Evolocumab
Administered by subcutaneous injection

Treatment: drugs: Placebo
Administered by subcutaneous injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 - LDL-C was quantified using the ultracentrifugation method.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 - LDL-C was quantified using the ultracentrifugation method.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Change From Baseline in LDL-C at Week 12 - LDL-C was quantified using the ultracentrifugation method.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Percent Change From Baseline in Apolipoprotein B at Week 12</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Percentage of Participants With 15% or Greater Reduction in LDL-C From Baseline at Week 12 - LDL-C was quantified using the ultracentrifugation method.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) at Week 12</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Percent Change From Baseline in LDL-C at the Mean of Weeks 6 and 12 - LDL-C was quantified using the ultracentrifugation method.</outcome>
      <timepoint>Baseline and Weeks 6 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Percent Change From Baseline in Apolipoprotein B at Week 12</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 6 and 12</outcome>
      <timepoint>Baseline and Weeks 6 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Percent Change From Baseline in Lipoprotein (a) at Week 12</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 6 and 12</outcome>
      <timepoint>Baseline and Weeks 6 and 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males and females = 12 to = 80 years of age

          -  Diagnosis of homozygous familial hypercholesterolemia

          -  Stable lipid-lowering therapies for at least 4 weeks

          -  LDL cholesterol = 130 mg/dl (3.4 mmol/L)

          -  Triglyceride = 400 mg/dL (4.5 mmol/L)

          -  Bodyweight of = 40 kg at screening.</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  LDL or plasma apheresis within 8 weeks prior to randomization

          -  New York Heart Association (NYHA) class III or IV or last known left ventricular
             ejection fraction &lt; 30%

          -  Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),
             coronary artery bypass graft (CABG) or stroke within 3 months of randomization

          -  Planned cardiac surgery or revascularization

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>58</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>La Louvi√®re</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Uherske Hradiste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 13</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>New Territories</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Beirut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andaluc√≠a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Galicia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in
      patients with homozygous familial hypercholesterolemia (HoFH).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01588496</trialwebsite>
    <publication>Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 Nov 5;128(19):2113-20. doi: 10.1161/CIRCULATIONAHA.113.004678. Epub 2013 Sep 6.
Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):341-50. doi: 10.1016/S0140-6736(14)61374-X. Epub 2014 Oct 1.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>